Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 15;22(22):12338.
doi: 10.3390/ijms222212338.

An Oligomannuronic Acid-Sialic Acid Conjugate Capable of Inhibiting Aβ42 Aggregation and Alleviating the Inflammatory Response of BV-2 Microglia

Jianrong Wu  1 , Miaosen Wu  1 , Hongtao Zhang  1 , Xiaobei Zhan  1 , Nian Wu  2
Affiliations

An Oligomannuronic Acid-Sialic Acid Conjugate Capable of Inhibiting Aβ42 Aggregation and Alleviating the Inflammatory Response of BV-2 Microglia

Jianrong Wu et al. Int J Mol Sci. .

Abstract

Oligomannuronic acid (MOS) from seaweed has antioxidant and anti-inflammatory activities. In this study, MOS was activated at the terminal to obtain three different graft complexes modified with sialic acid moiety (MOS-Sia). The results show that MOS-Sia addition can reduce the β-structure formation of Aβ42, and the binding effect of MOS-Sia3 is more obvious. MOS-Sia conjugates also have a better complexing effect with Ca2+ while reducing the formation of Aβ42 oligomers in solutions. MOS-Sia3 (25-50 μg/mL) can effectively inhibit the activation state of BV-2 cells stimulated by Aβ42, whereas a higher dose of MOS-Sia3 (>50 μg/mL) can inhibit the proliferation of BV-2 cells to a certain extent. A lower dose of MOS-Sia3 can also inhibit the expression of IL-1β, IL-6, TNF-α, and other proinflammatory factors in BV-2 cells induced by Aβ42 activation. In the future, the MOS-Sia3 conjugate can be used to treat Alzheimer's disease.

Keywords: Alzheimer’s disease; microglia; oligomannuronic acid; sialic acid; β-amyloid.

PubMed Disclaimer

Conflict of interest statement

There are no conflict to declare.

Figures

Figure 1
Figure 1
MS spectra of MOS-Sia. (a) MOS-Sia1, (b) MOS-Sia2, and (c) MOS-Sia3.
Figure 1
Figure 1
MS spectra of MOS-Sia. (a) MOS-Sia1, (b) MOS-Sia2, and (c) MOS-Sia3.
Figure 2
Figure 2
Residual soluble Aβ in supernatant after interaction with MOS-Sia, metal ion, and Aβ42. Note: Molar ratio of Aβ42 to metal ion was set as 1:1, with incubation for 24 h. Data are shown as the mean ± SD of triplicates.
Figure 3
Figure 3
Fluorescence detection of the effect of MOS-Sia on Aβ42 aggregation by ThT staining. Data are shown as the mean ± SD of triplicates.
Figure 4
Figure 4
CD analysis of the interaction between MOS-Sia and Aβ42.
Figure 5
Figure 5
Effect of MOS-Sia3 on the cell growth of BV-2. Data are shown as the mean ± SD of triplicates.
Figure 6
Figure 6
Morphological observation of BV-2 cells after administration with MOS-Sia3 and Aβ42.
Figure 7
Figure 7
Effects of MOS-Sia3 on cytokine secretion in BV-2 cells induced by Aβ42. Captions: Black bar, 24 h of culture; gray bar: 48 h of culture. Data are shown as the mean ± SD of triplicates with good reproducibility. SD is represented as error bars. Statistically significant differences are indicated: ** for p ≤ 0.01, and *** for p ≤ 0.001.
Figure 7
Figure 7
Effects of MOS-Sia3 on cytokine secretion in BV-2 cells induced by Aβ42. Captions: Black bar, 24 h of culture; gray bar: 48 h of culture. Data are shown as the mean ± SD of triplicates with good reproducibility. SD is represented as error bars. Statistically significant differences are indicated: ** for p ≤ 0.01, and *** for p ≤ 0.001.
Scheme 1
Scheme 1
Preparation of MOS-Sia by reductive amination, amidation, and thiol condensation.
See this image and copyright information in PMC

References

    1. Sošić M., Vuletic V., Tomić Z., Bogdanovic N. Diagnostic and therapeutic approach to a patient with cognitive impairment. Med. Flum. 2018;54:140–154. doi: 10.21860/medflum2018_198234. - DOI
    1. Cummings J., Lee G., Ritter A., Sabbagh M., Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimer’s Dement. Transl. Res. Clin. Interv. 2019;5:272–293. doi: 10.1016/j.trci.2019.05.008. - DOI - PMC - PubMed
    1. Hukins D., MacLeod U., Boland J.W. Identifying potentially inappropriate prescribing in older people with dementia: A systematic review. Eur. J. Clin. Pharmacol. 2019;75:467–481. doi: 10.1007/s00228-018-02612-x. - DOI - PubMed
    1. Tagliavini F., Tiraboschi P., Federico A. Alzheimer’s disease: The controversial approval of Aducanumab. Neurol. Sci. 2021;42:3069–3070. doi: 10.1007/s10072-021-05497-4. - DOI - PubMed
    1. Flynn R.A., Pedram K., Malaker S.A., Batista P.J., Smith B.A., Johnson A.G., George B.M., Majzoub K., Villalta P.W., Carette J.E., et al. Small RNAs are modified with N-glycans and displayed on the surface of living cells. Cell. 2021;184:3109–3124.e22. doi: 10.1016/j.cell.2021.04.023. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources